Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

Immunogenicity and safety following receipt of the standard SARS–CoV‐2 vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are poorly characterized, and data after receipt of the third vaccine dose are lacking. The aim of the study was to evaluate serologic responses and adverse events following the standard 2‐dose regimen and a third dose of SARS–CoV‐2 vaccine in IMID patients receiving immunosuppressive therapy.

[1]  S. Subhadarshani,et al.  Clinical Images: Hydroxyurea‐induced dermatomyositis‐like rash , 2022 .

[2]  D. Follmann,et al.  Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.

[3]  F. Lund-Johansen,et al.  Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera , 2022 .

[4]  J. Izopet,et al.  Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients , 2021, American Journal of Transplantation.

[5]  F. Lund-Johansen,et al.  Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study , 2021, The Lancet Rheumatology.

[6]  D. Weinberger,et al.  Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. , 2021, JAMA internal medicine.

[7]  T. Harrer,et al.  Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.

[8]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[9]  M. Davenport,et al.  Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.

[10]  J. Gottenberg,et al.  Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab , 2021, The Lancet Rheumatology.

[11]  S. Higa,et al.  Rapid attenuation of anti-SARS-CoV-2 antibody in patients with musculoskeletal diseases who reinitiated intensive immunosuppressive therapies after COVID-19. , 2021, Arthritis & rheumatology.

[12]  F. Lund-Johansen,et al.  Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  D. McGovern,et al.  Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease , 2021, Annals of Internal Medicine.

[14]  B. Ludewig,et al.  Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses , 2021, The Lancet Rheumatology.

[15]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[16]  J. Albayda,et al.  Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series , 2021, Annals of the Rheumatic Diseases.

[17]  J. Curtis,et al.  Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[18]  Gregory F. Wu,et al.  Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.

[19]  L. Heylen,et al.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[20]  M. Neurath,et al.  Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. , 2021, The New England journal of medicine.

[21]  Andrew T. Kroger,et al.  American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 , 2021, Arthritis & rheumatology.

[22]  N. Kennedy,et al.  Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis , 2021, Autoimmunity Reviews.

[23]  M. Boers,et al.  Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies , 2021, The Lancet Rheumatology.

[24]  P. Gallian,et al.  SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  M. Dubinsky,et al.  Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease , 2021, Gastroenterology.

[26]  G. Shefer,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.

[27]  D. McGovern,et al.  Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease , 2021, The American journal of gastroenterology.

[28]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[29]  Colin Simpson,et al.  Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study , 2021, The Lancet.

[30]  C. Lees,et al.  Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab , 2021, Gut.

[31]  L. Peyrin-Biroulet,et al.  SARS-CoV-2 vaccination in IBD: more pros than cons , 2021, Nature Reviews Gastroenterology & Hepatology.

[32]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[33]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[34]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[35]  F. Underwood,et al.  Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.

[36]  Karl Erik Müller,et al.  Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients , 2020, Proceedings of the National Academy of Sciences.

[37]  A. Vojdani,et al.  Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.

[38]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[39]  E. S. El-Din,et al.  Hydroxyurea‐induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis‐like eruption? , 2012, International journal of dermatology.

[40]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[41]  J. Callen,et al.  Hydroxyurea-induced dermatomyositis-like eruption. , 2003, Journal of the American Academy of Dermatology.

[42]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[43]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.